AOC3 and sclerosing cholangitis: Expression of VAP-1 has been described in patients with rheumatoid arthritis and patients with primary sclerosing cholangitis [12, 13], and several publications describe VAP-1-targeted in vivo imaging in various experimental disease models [14–16].